

## Freedom of Information (Scotland) Act 2002

<b>DATE RECEIVED</b>	<b>06/07/2022</b>	<b>SUBJECT</b>	<b>Radium-223</b>		
<b>PASSED TO</b>	<b>Macmillan Medical Physics</b>	<b>DATE PASSED</b>	<b>06/07/2022</b>	<b>RESPOND BY</b>	<b>27/06/2022</b>
<b>CATEGORY</b>	<b>Business</b>	<b>FoI NUMBER</b>	<b>2022-251</b>		

Question/s to be Answered

These questions are not applicable to NHS Shetland. There is no radiotherapy service here.

### Question 1

Please complete the table below:

<b>Radium-223 dichloride service</b>	
Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n)	
If yes, please list the indications for which it is used in your trust?	

### Question 2

Please detail the number of patients that are treated with radium-223 dichloride in your trust:

<b>Patient numbers</b>	
Number of prostate cancer patients completing treatment with radium-223 dichloride per year	
Number of prostate cancer patients initiating radium-223 dichloride treatment per year	
What is the average number of cycles administered per patient in your service?	
What is the waiting time before patients can receive radium-223 dichloride?	
How many patients are initiated with cabazitaxel per year in your trust?	

### Question 3

In what department is molecular radiotherapy provided in your trust?

<b>Administration</b>	Radium-223 dichloride	177Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine		
Medical Physics		

## Freedom of Information (Scotland) Act 2002

Radiotherapy		
Oncology		
Urology		
Other		
N/A		

### Question 4

What codes are associated with molecular radiotherapy administration in your trust?

NHS codes	HRG	OPCS code
Radium-223 dichloride		

### Question 5

Please complete the table below:

Who performs the administration of the treatment?	Radium-223 dichloride	<sup>177</sup> Lutetium based radioligand therapy for neuroendocrine tumours
CNS		
Technician		
NM nurse		
NM physicist		
NM Consultant		
Oncologist		
Other ( <i>please state</i> )		

### Question 6

Who holds the ARSAC licence in your trust?

Administration	(y/n)	Radium-223 dichloride	<sup>177</sup> Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine consultant			
Clinical Oncologist			
Radiologist			
Other ( <i>please state speciality</i> )			

## Freedom of Information (Scotland) Act 2002

### Question 7

Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

Radiation safety (y/n)	Conducted in-house  <i>(If so, please provide the number of full-time equivalents providing these services in your centre)</i>	Outsourced
Radioactive Waste Adviser (RWA)		
Radiation Protection Adviser (RPA)		
Medical Physics Expert (MPE)		

### Question 8

Please complete the table below:

Dosimetry	(y/n)	If yes, what is the schedule after each administration?	If yes, is this analysed in-house or outsourced?
Is dosimetry performed for radium-223 dichloride prostate cancer patients?			

Please let us know if you require any further information to process this request or if this request needs to be directed elsewhere.

Please send all replies to: [OHSMA\\_FOI@OpenHealthGroup.com](mailto:OHSMA_FOI@OpenHealthGroup.com)